MCID: PLY001
MIFTS: 74

Polycythemia Vera

Categories: Genetic diseases, Rare diseases, Cancer diseases, Blood diseases

Aliases & Classifications for Polycythemia Vera

MalaCards integrated aliases for Polycythemia Vera:

Name: Polycythemia Vera 57 12 76 53 25 59 75 37 29 13 55 6 44 15 38 63 40 73
Pv 57 53 25 59 75
Polycythemia Rubra Vera 57 53 59 75
Prv 57 53 25 75
Osler-Vaquez Disease 25 59 75
Primary Polycythemia 53 25
Acquired Primary Erythrocytosis 59
Polycythemia Rubra Vera; Prv 57
Proliferative Polycythaemia 12
Polycythemia Vera, Somatic 57
Polycythaemia Rubra Vera 12
Polycythemia Ruba Vera 25
Osler-Vaquez Syndrome 12
Vaquez Disease 59

Characteristics:

Orphanet epidemiological data:

59
polycythemia vera
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-5/10000 (Europe); Age of onset: All ages; Age of death: normal life expectancy;

OMIM:

57
Inheritance:
somatic mutation

Miscellaneous:
mean age at onset 57-60 years
children rarely develop the disorder
familial cases are rare and show incomplete penetrance
distinct disorder from familial erythrocytosis (ecyt1, )


HPO:

32

Classifications:



Summaries for Polycythemia Vera

NIH Rare Diseases : 53 Polycythemia vera is a condition characterized by an increased number of red blood cells in the bloodstream (erythrocytosis). Affected people may also have excess white blood cells and platelets. Conditions where the body makes too many of these cells are known as myeloproliferative neoplasms. These extra cells cause the blood to be thicker than normal, increasing the risk for blood clots that can block blood flow in arteries and veins. If a blood clot occurs in the veins deep in the arms and the legs, it is known as deep vein thrombosis (DVT). A DVT can sometimes travel through the blood stream to the lungs, which can cause a pulmonary embolism and is very dangerous. A blood clot could also travel to the heart or brain, which leads to an increased risk for heart attack or stroke. Most cases of PV are not inherited and are acquired during a person’s lifetime. PV is more common as a person ages, and it typically presents for the first time around 60-years-old. PV occurs more frequently in men than it does in women. The condition has been associated with mutations in the JAK2 and TET2 genes. In rare cases, the risk for PV runs in families and may be inherited in an autosomal dominant manner.

MalaCards based summary : Polycythemia Vera, also known as pv, is related to primary polycythemia and polycythemia. An important gene associated with Polycythemia Vera is JAK2 (Janus Kinase 2), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Zinc and Lactitol have been mentioned in the context of this disorder. Affiliated tissues include bone, myeloid and bone marrow, and related phenotypes are gingival bleeding and tinnitus

OMIM : 57 Polycythemia vera, the most common form of primary polycythemia, is caused by somatic mutation in a single hematopoietic stem cell leading to clonal hematopoiesis. PV is a myeloproliferative disorder characterized predominantly by erythroid hyperplasia, but also by myeloid leukocytosis, thrombocytosis, and splenomegaly. Familial cases of PV are very rare and usually manifest in elderly patients (Cario, 2005). PV is distinct from the familial erythrocytoses (see, e.g., ECYT1, 133100), which are caused by inherited mutations resulting in hypersensitivity of erythroid progenitors to hormonal influences or increased levels of circulating hormones, namely erythropoietin (EPO; 133170) (Prchal, 2005). (263300)

UniProtKB/Swiss-Prot : 75 Polycythemia vera: A myeloproliferative disorder characterized by abnormal proliferation of all hematopoietic bone marrow elements, erythroid hyperplasia, an absolute increase in total blood volume, but also by myeloid leukocytosis, thrombocytosis and splenomegaly.

Genetics Home Reference : 25 Polycythemia vera is a condition characterized by an increased number of red blood cells in the bloodstream. Affected individuals may also have excess white blood cells and blood clotting cell fragments called platelets. These extra cells and platelets cause the blood to be thicker than normal. As a result, abnormal blood clots are more likely to form and block the flow of blood through arteries and veins. Individuals with polycythemia vera have an increased risk of deep vein thrombosis (DVT), a type of blood clot that occurs in the deep veins of the arms or legs. If a DVT travels through the bloodstream and lodges in the lungs, it can cause a life-threatening clot known as a pulmonary embolism (PE). Affected individuals also have an increased risk of heart attack and stroke caused by blood clots in the heart and brain.

PubMed Health : 63 About polycythemia vera: Polycythemia vera (POL-e-si-THEE-me-ah VAY-rah or VE-rah), or PV, is a rare blood disease in which your body makes too many red blood cells.The extra red blood cells make your blood thicker than normal. As a result, blood clots can form more easily. These clots can block blood flow through your arteries and veins, which can cause a heart attack or stroke.Thicker blood also doesn't flow as quickly to your body as normal blood. Slowed blood flow prevents your organs from getting enough oxygen, which can cause serious problems, such as angina (an-JI-nuh or AN-juh-nuh) and heart failure. (Angina is chest pain or discomfort.)

Wikipedia : 76 Polycythemia vera is an uncommon neoplasm in which the bone marrow makes too many red blood cells. It... more...

Related Diseases for Polycythemia Vera

Diseases related to Polycythemia Vera via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 241)
# Related Disease Score Top Affiliating Genes
1 primary polycythemia 33.3 EPO EPOR IL3 JAK2
2 polycythemia 32.1 CD177 EPO EPOR IL3 JAK1 JAK2
3 splenomegaly 31.7 EPO JAK2 MPL
4 thrombocytosis 31.1 EPO IL3 JAK2 MPL TET2 THPO
5 myeloid leukemia 30.9 IL3 JAK2 KIT TET2
6 pancytopenia 30.6 EPO IL3 MPL THPO
7 essential thrombocythemia 30.6 CD177 EPO EPOR IL3 JAK2 MPL
8 refractory anemia 30.5 EPO IL3 JAK2 MPL TET2
9 deficiency anemia 30.5 EPO EPOR IL3 THPO
10 neutropenia 30.3 CD177 EPO IL3 KITLG THPO
11 chronic myelomonocytic leukemia 30.3 JAK2 KIT PDGFRB TET2
12 myeloproliferative neoplasm 30.2 H19 JAK2 KIT MPL PDGFRA PDGFRB
13 hepatitis c 30.1 JAK1 SOCS3 STAT3 TYK2
14 myelofibrosis 30.0 CD177 EPO HMGA2 IL3 JAK1 JAK2
15 leukemia, acute myeloid 29.8 IL3 JAK2 KIT KITLG MPL STAT3
16 myelodysplastic syndrome 28.6 EPO EPOR IL3 JAK2 KIT KITLG
17 leukemia, chronic myeloid 27.3 CD177 EPO H19 IL3 JAK2 KIT
18 psoriasis 1 11.5
19 budd-chiari syndrome 11.5
20 erythromelalgia 11.5
21 aquagenic pruritus 11.5
22 persistent vegetative state 11.2
23 pemphigus vulgaris, familial 11.2
24 hemoglobin, high altitude adaptation 11.1
25 psoriasis 14, pustular 11.0
26 pulmonary valve stenosis 11.0
27 acquired polycythemia 10.9 EPO EPOR JAK2
28 thrombocytopenia 3 10.9 MPL THPO
29 folic acid deficiency anemia 10.9 EPO TET2 THPO
30 porphyria variegata 10.9
31 psoriasis 2 10.9
32 psoriasis 7 10.9
33 psoriasis 11 10.9
34 psoriasis 13 10.9
35 plummer vinson syndrome 10.9
36 transient erythroblastopenia of childhood 10.9 EPO KITLG
37 retinitis pigmentosa and erythrocytic microcytosis 10.9 EPO IL3 JAK2
38 acute erythroid leukemia 10.9 EPO EPOR JAK2
39 thrombocythemia 1 10.8 MPL THPO
40 thrombocytopenia-absent radius syndrome 10.8 JAK2 MPL THPO
41 blood coagulation disease 10.8 JAK2 MPL THPO
42 amegakaryocytic thrombocytopenia, congenital 10.8 IL3 MPL THPO
43 deep leiomyoma 10.8 CD177 KIT
44 hemorrhagic disease 10.8 JAK2 MPL THPO
45 chromosome 5q deletion syndrome 10.8 EPO TET2
46 blood platelet disease 10.8 JAK2 MPL THPO
47 lactocele 10.8 JAK1 JAK2 JAK3
48 lymphoblastic leukemia, acute, with lymphomatous features 10.8 JAK1 JAK2 JAK3
49 mixed lacrimal gland cancer 10.7 JAK1 STAT3 TYK2
50 dyskeratosis congenita, autosomal dominant 6 10.7 MPL THPO

Graphical network of the top 20 diseases related to Polycythemia Vera:



Diseases related to Polycythemia Vera

Symptoms & Phenotypes for Polycythemia Vera

Symptoms via clinical synopsis from OMIM:

57
AbdomenSpleen:
splenomegaly

Cardiovascular Vascular:
cerebral ischemia
budd-chiari syndrome
thrombosis
thromboembolic events

Abdomen Gastrointestinal:
gastrointestinal bleeding

Laboratory Abnormalities:
normal or decreased serum erythropoietin (epo, )
increased prv-1 mrna
erythroid colony-forming units show spontaneous growth in the absence of epo
normal arterial oxygen saturation

Hematology:
thrombocytopenia
thrombocytosis
leukocytosis
increased hematocrit
increased red blood cell mass
more
Neurologic Central Nervous System:
cerebral ischemia
cerebral hemorrhage

Cardiovascular Heart:
myocardial ischemia


Clinical features from OMIM:

263300

Human phenotypes related to Polycythemia Vera:

59 32 (show all 39)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 gingival bleeding 59 32 hallmark (90%) Very frequent (99-80%) HP:0000225
2 tinnitus 59 32 hallmark (90%) Very frequent (99-80%) HP:0000360
3 epistaxis 59 32 hallmark (90%) Very frequent (99-80%) HP:0000421
4 bruising susceptibility 59 32 hallmark (90%) Very frequent (99-80%) HP:0000978
5 pruritus 59 32 occasional (7.5%) Occasional (29-5%) HP:0000989
6 stroke 59 32 occasional (7.5%) Occasional (29-5%) HP:0001297
7 portal hypertension 59 32 occasional (7.5%) Occasional (29-5%) HP:0001409
8 angina pectoris 59 32 hallmark (90%) Very frequent (99-80%) HP:0001681
9 splenomegaly 59 32 hallmark (90%) Very frequent (99-80%) HP:0001744
10 weight loss 59 32 hallmark (90%) Very frequent (99-80%) HP:0001824
11 abdominal pain 59 32 hallmark (90%) Very frequent (99-80%) HP:0002027
12 respiratory insufficiency 59 32 frequent (33%) Frequent (79-30%) HP:0002093
13 pulmonary embolism 59 32 occasional (7.5%) Occasional (29-5%) HP:0002204
14 gastrointestinal hemorrhage 59 32 occasional (7.5%) Occasional (29-5%) HP:0002239
15 hepatomegaly 59 32 hallmark (90%) Very frequent (99-80%) HP:0002240
16 headache 59 32 hallmark (90%) Very frequent (99-80%) HP:0002315
17 vertigo 59 32 hallmark (90%) Very frequent (99-80%) HP:0002321
18 acute leukemia 59 32 hallmark (90%) Very frequent (99-80%) HP:0002488
19 budd-chiari syndrome 59 32 occasional (7.5%) Occasional (29-5%) HP:0002639
20 arthralgia 59 32 frequent (33%) Frequent (79-30%) HP:0002829
21 myelodysplasia 59 32 hallmark (90%) Very frequent (99-80%) HP:0002863
22 intermittent claudication 59 32 occasional (7.5%) Occasional (29-5%) HP:0004417
23 arterial thrombosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0004420
24 myelofibrosis 59 32 hallmark (90%) Very frequent (99-80%) HP:0011974
25 fatigue 59 32 frequent (33%) Frequent (79-30%) HP:0012378
26 portal vein thrombosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0030242
27 hypertension 59 Very frequent (99-80%)
28 venous thrombosis 59 Occasional (29-5%)
29 cerebral hemorrhage 32 HP:0001342
30 thrombocytopenia 32 HP:0001873
31 thrombocytosis 32 HP:0001894
32 increased red blood cell mass 32 HP:0001898
33 increased hematocrit 32 HP:0001899
34 increased hemoglobin 32 HP:0001900
35 thromboembolism 32 HP:0001907
36 leukocytosis 32 HP:0001974
37 abnormal thrombosis 32 HP:0001977
38 cerebral ischemia 32 HP:0002637
39 increased megakaryocyte count 32 HP:0005513

GenomeRNAi Phenotypes related to Polycythemia Vera according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in HMC1.1 cells GR00105-A-0 8.8 JAK3 KIT JAK1

MGI Mouse Phenotypes related to Polycythemia Vera:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.36 EPO JAK2 EPOR JAK3 JAK1 KIT
2 cellular MP:0005384 10.35 EPO JAK2 EPOR JAK3 KIT PDGFRA
3 immune system MP:0005387 10.31 CD177 EPO JAK2 EPOR JAK3 JAK1
4 growth/size/body region MP:0005378 10.26 JAK1 JAK2 EPOR MPL KIT PDGFRA
5 cardiovascular system MP:0005385 10.25 JAK1 EPO EPOR KIT PDGFRA KITLG
6 homeostasis/metabolism MP:0005376 10.25 JAK1 EPO JAK2 EPOR MPL KIT
7 embryo MP:0005380 10.21 EPO JAK2 EPOR MPL KIT PDGFRA
8 endocrine/exocrine gland MP:0005379 10.15 JAK1 JAK2 JAK3 KIT PDGFRA KITLG
9 mortality/aging MP:0010768 10.1 EPO JAK2 EPOR JAK3 JAK1 MPL
10 digestive/alimentary MP:0005381 10.07 JAK3 KIT PDGFRA KITLG SOCS3 PDGFRB
11 integument MP:0010771 10.02 JAK1 EPO JAK2 KIT PDGFRA KITLG
12 liver/biliary system MP:0005370 9.97 EPO JAK2 EPOR JAK1 KITLG KIT
13 normal MP:0002873 9.85 EPO JAK2 EPOR JAK1 KIT PDGFRA
14 respiratory system MP:0005388 9.5 JAK1 EPO EPOR KIT PDGFRA SOCS3
15 skeleton MP:0005390 9.32 JAK1 EPO JAK2 KIT PDGFRA KITLG

Drugs & Therapeutics for Polycythemia Vera

PubMedHealth treatment related to Polycythemia Vera: 63

Polycythemia vera (PV) doesn't have a cure. However, treatments can help control the disease and its complications. PV is treated with procedures, medicines, and other methods. You may need one or more treatments to manage the disease.

Drugs for Polycythemia Vera (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 263)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc Approved, Investigational Phase 4 7440-66-6 23994
2
Lactitol Investigational Phase 4 585-86-4 3871
3
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
4
Busulfan Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 55-98-1 2478
5
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 498142 38904
6
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
7
Fludarabine Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 21679-14-1, 75607-67-9 30751
8
Hydroxyurea Approved Phase 3,Phase 2,Phase 1 127-07-1 3657
9
Peginterferon alfa-2b Approved Phase 3,Phase 1,Phase 2 99210-65-8, 215647-85-1
10
Aspirin Approved, Vet_approved Phase 3,Phase 2 50-78-2 2244
11
Peginterferon alfa-2a Approved, Investigational Phase 3,Phase 2,Phase 1 198153-51-4 5360545
12
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
13
Ondansetron Approved Phase 3,Phase 1,Phase 2,Not Applicable 99614-02-5 4595
14
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
15
Caspofungin Approved Phase 3,Phase 2 179463-17-3, 162808-62-0 468682 2826718
16
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
17
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
18
Guaifenesin Approved, Investigational, Vet_approved Phase 3,Not Applicable 93-14-1 3516
19
Morphine Approved, Investigational Phase 3,Not Applicable 57-27-2 5288826
20
Anagrelide Approved Phase 3,Phase 2 68475-42-3 2182
21
Lenalidomide Approved Phase 3,Phase 2 191732-72-6 216326
22 Pomalidomide Approved Phase 3,Phase 1,Phase 2 19171-19-8
23
Etoposide Approved Phase 2, Phase 3,Phase 1 33419-42-0 36462
24
Melphalan Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 148-82-3 4053 460612
25
Thiotepa Approved, Investigational Phase 2, Phase 3,Phase 1 52-24-4 5453
26
Benzocaine Approved, Investigational Phase 3,Phase 1,Phase 2 1994-09-7, 94-09-7 2337
27
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1 147-94-4 6253
28
Danazol Approved Phase 3,Phase 2 17230-88-5 28417
29
Iron Approved Phase 3,Phase 1,Phase 2 7439-89-6 23925
30
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
31
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
32 tannic acid Approved, Nutraceutical Phase 3,Phase 1,Phase 2
33 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
34 Analgesics Phase 3,Phase 2,Phase 1,Not Applicable
35 Anesthetics Phase 3
36 Anesthetics, Dissociative Phase 3
37 Anesthetics, General Phase 3
38 Anesthetics, Intravenous Phase 3
39 Central Nervous System Depressants Phase 3,Phase 1,Phase 2,Not Applicable
40 Excitatory Amino Acid Antagonists Phase 3
41 Excitatory Amino Acids Phase 3
42 Neurotransmitter Agents Phase 3,Phase 2,Not Applicable
43 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1,Not Applicable
44 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
45 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
46 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable
47 Dermatologic Agents Phase 3,Phase 2,Phase 1,Not Applicable
48 Anti-Bacterial Agents Phase 3,Phase 1,Phase 2,Not Applicable
49 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
50 Alkylating Agents Phase 2, Phase 3,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 243)
# Name Status NCT ID Phase Drugs
1 CINC424A2X01B Rollover Protocol Recruiting NCT02386800 Phase 4 Ruxolitinib
2 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
3 Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study Completed NCT01632904 Phase 3 Ruxolitinib;Hydroxyurea (HU);HU-placebo;Ruxolitinib-placebo
4 Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients Completed NCT02523638 Phase 3 Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen
5 Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera Completed NCT01949805 Phase 3 Peg-P-IFN-alpha-2b (AOP2014);Hydroxyurea
6 Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Completed NCT01259856 Phase 3 PEGASYS;Hydroxyurea;Aspirin
7 A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis Completed NCT02087059 Phase 3 Ruxolitinib
8 COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial Completed NCT00952289 Phase 3 Ruxolitinib;Placebo
9 Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial Completed NCT00934544 Phase 3 INC424/INCB018424;Best Available Therapy (BAT)
10 Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis Completed NCT01437787 Phase 3 SAR302503;Placebo
11 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
12 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
13 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
14 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
15 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
16 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
17 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
18 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
19 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
20 Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy. Recruiting NCT02038036 Phase 3 Best Available Therapy;ruxolitinib
21 Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Are Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Are Available. Recruiting NCT02292446 Phase 3 Ruxolitinib
22 AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study. Active, not recruiting NCT02218047 Phase 3 Pegylated-Proline-interferon alpha-2b;Best available therapy (BAT)
23 Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial) Active, not recruiting NCT01243944 Phase 3 ruxolitinib tablets
24 Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF Active, not recruiting NCT02101268 Phase 3 Momelotinib;Best Available Therapy (BAT)
25 Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis Active, not recruiting NCT01969838 Phase 3 Momelotinib;Ruxolitinib;Placebo to match momelotinib;Placebo to match ruxolitinib
26 A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms Active, not recruiting NCT01387763 Phase 3 PegIntron;Pegasys;PegIntron;Pegasys;Hydrea
27 Phase-3 Double-Blind, Placebo-Controlled Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence Myelofibrosis and RBC-Transfusion-Dependence Active, not recruiting NCT01178281 Phase 3 Pomalidomide 0.5 mg;Placebo
28 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
29 Large-scale Trial Testing the Intensity of CYTOreductive Therapy in Polycythemia Vera (PV) Terminated NCT01645124 Phase 3 Hydroxyurea
30 Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia Terminated NCT02055781 Phase 3 Pacritinib;Best Available Therapy
31 Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis Terminated NCT01773187 Phase 3 Pacritinib;Best Available Therapy
32 A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia Unknown status NCT00866762 Phase 2 HDAC inhibitor (MK-0683)
33 CEP-701 (Lestaurtinib) in Myelofibrosis Unknown status NCT00668421 Phase 1, Phase 2 CEP-701 (Lestaurtinib)
34 LBH589 (Panobinostat) for the Treatment of Myelofibrosis Unknown status NCT01298934 Phase 1, Phase 2 LBH589
35 Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia Vera Completed NCT00928707 Phase 2 GIVINOSTAT (ITF2357) 50 mg o.d. + MTD Hydroxyurea;GIVINOSTAT (ITF2357) 50 mg b.i.d. + MTD Hydroxyurea
36 A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera Completed NCT01901432 Phase 1, Phase 2 Givinostat
37 Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Completed NCT01259817 Phase 2 PEGASYS;Aspirin
38 Treatment of Polycythemia Vera With Gleevec Completed NCT01120821 Phase 2 Gleevec
39 Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera Completed NCT00241241 Phase 2 pegylated interferon-alfa 2a
40 Effects of Imatinib Mesylate in Polycythemia Vera Completed NCT00430066 Phase 2 Imatinib Mesylate
41 Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera Completed NCT01243073 Phase 2 Imetelstat
42 Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis Completed NCT00586651 Phase 2 lestaurtinib
43 Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera Completed NCT01193699 Phase 1, Phase 2 PEG-P-INF alpha-2b (P1101)
44 Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis Completed NCT00509899 Phase 1, Phase 2 Ruxolitinib
45 Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis Completed NCT01423058 Phase 1, Phase 2 Momelotinib
46 Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) Completed NCT01236638 Phase 2 Momelotinib
47 Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) Completed NCT00935987 Phase 1, Phase 2 CYT387
48 Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) Completed NCT02515630 Phase 2 MMB
49 Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis Completed NCT01369498 Phase 2 Simtuzumab;Ruxolitinib
50 Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia Completed NCT01420783 Phase 2 SAR302503

Search NIH Clinical Center for Polycythemia Vera

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: polycythemia vera

Genetic Tests for Polycythemia Vera

Genetic tests related to Polycythemia Vera:

# Genetic test Affiliating Genes
1 Polycythemia Vera 29 JAK2

Anatomical Context for Polycythemia Vera

MalaCards organs/tissues related to Polycythemia Vera:

41
Bone, Myeloid, Bone Marrow, Heart, Lung, Brain, T Cells

Publications for Polycythemia Vera

Articles related to Polycythemia Vera:

(show top 50) (show all 893)
# Title Authors Year
1
Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis. ( 29226426 )
2018
2
Impact of hydroxycarbamide and interferon-I+ on red cell adhesion and membrane protein expression in polycythemia vera. ( 29599206 )
2018
3
Serum ferritin as a biomarker of polycythemia vera? ( 29765288 )
2018
4
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. ( 29734070 )
2018
5
Evidence- and consensus-based recommendations for phlebotomy in polycythemia vera. ( 29955128 )
2018
6
Aquagenic Pruritus in Polycythemia Vera: Clinical Characteristics. ( 29437189 )
2018
7
Distinguishing myelofibrosis from polycythemia vera and essential thrombocythemia: The utility of enumerating circulating stem cells with aberrant hMICL expression by flow cytometry. ( 29427319 )
2018
8
Polycythemia vera treatment algorithm 2018. ( 29321547 )
2018
9
The WHO diagnostic criteria for polycythemia vera-role of red cell mass versus hemoglobin/hematocrit level and morphology. ( 29717365 )
2018
10
Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data. ( 29335456 )
2018
11
Safety and efficacy of combination therapy of interferon-I+2 and ruxolitinib in polycythemia vera and myelofibrosis. ( 29932310 )
2018
12
The real-world outcomes of treating Polycythemia Vera: Physician adherence to treatment guidelines. ( 29885533 )
2018
13
Polycythemia vera and essential thrombocythemia: algorithmic approach. ( 29194068 )
2018
14
Bone marrow findings in blast phase of polycythemia vera. ( 29285580 )
2018
15
Cytoreductive treatment patterns among US veterans with polycythemia vera. ( 29728092 )
2018
16
Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up. ( 29181548 )
2018
17
A Novel Acquired t(2;4)(q36.1;q24) with a Concurrent Submicroscopic del(4)(q23q24) in An Adult with Polycythemia Vera. ( 29941837 )
2018
18
Congenital methemoglobinemia misdiagnosed as polycythemia vera: Case report and review of literature. ( 29721250 )
2018
19
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. ( 29622658 )
2018
20
Health Care Costs and Thromboembolic Events in Hydroxyurea-Treated Patients with Polycythemia Vera. ( 29290171 )
2018
21
Molecular evidence of JAK2 p.V617F mutated pure erythroid leukemia arising from polycythemia vera. ( 29611054 )
2018
22
Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial. ( 29804268 )
2018
23
Unmasking and aggravation of polycythemia vera by canagliflozin. ( 29888479 )
2018
24
Prognostic factors for thrombosis-free survival and overall survival in polycythemia vera: A retrospective analysis of 623 PTS With long follow-up. ( 29625320 )
2018
25
Improvement in Ulcerative Necrobiosis Lipoidica After Janus Kinase-Inhibitor Therapy for Polycythemia Vera. ( 29800055 )
2018
26
Distinctive CD8<sup>+</sup> T cell and MHC class I signatures in polycythemia vera patients. ( 29789880 )
2018
27
Ruxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera with splenomegaly. ( 28956263 )
2018
28
Increased plasma viscosity in plasma cell dyscrasia and whole blood viscosity in polycythemia vera. ( 29660912 )
2018
29
Pegylated interferon Alfa-2a and hydroxyurea in polycythemia vera and essential thrombocythemia: differential cellular and molecular responses. ( 29556018 )
2018
30
Masked polycythemia Vera (mPV): Results of an international study. ( 29634089 )
2018
31
Prognostic risk model for patients with high-risk polycythemia vera and essential thrombocythemia. ( 29313725 )
2018
32
Neutropenia caused by hairy cell leukemia in a patient with myelofibrosis secondary to polycythemia vera: a case report. ( 29685167 )
2018
33
Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera. ( 28068330 )
2017
34
Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis. ( 28419183 )
2017
35
Thrombotic Thrombocytopenic Purpura Associated With Pegylated Interferon Alfa-2a Use in a Patient With Polycythemia Vera. ( 28596255 )
2017
36
Can pegylated interferon improve the outcome of polycythemia vera patients? ( 28086927 )
2017
37
Pulmonary Hypertension Associated with Pulmonary Veno-occlusive Disease in Patients with Polycythemia Vera. ( 28824072 )
2017
38
In the era of next generation sequencing, is the cytogenetic analysis still important in polycythemia vera? ( 28702402 )
2017
39
From leeches to personalized medicine: evolving concepts in the management of polycythemia vera. ( 27884974 )
2017
40
Pulmonary extra-medullary hematopoiesis and pulmonary hypertension from underlying polycythemia vera: a case series. ( 28680586 )
2017
41
Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients. ( 29282357 )
2017
42
Disease and treatment characteristics of polycythemia vera patients in Belgium: Results from a scientific survey. ( 29285836 )
2017
43
Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis. ( 28601551 )
2017
44
Erythrocytosis caused by giant chromophobe renal cell carcinoma: a case report indicating a 9-year misdiagnosis of polycythemia vera. ( 28877745 )
2017
45
A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia. ( 28622623 )
2017
46
Tumor Lysis Syndrome after the Administration of Ruxolitinib in a Patient with Post-polycythemia Vera Myelofibrosis. ( 28794380 )
2017
47
The Calreticulin control of human stress erythropoiesis is impaired by JAK2V617F in polycythemia vera. ( 28232234 )
2017
48
Anti-Platelet Factor 4/Heparin Antibody Formation Occurs Endogenously and at Unexpected High Frequency in Polycythemia Vera. ( 28698883 )
2017
49
The role of certain gene polymorphisms involved in the apoptotic pathways in polycythemia vera and essential thrombocytosis. ( 29068570 )
2017
50
Therapy of polycythemia vera: is it time to change? ( 29262518 )
2017

Variations for Polycythemia Vera

UniProtKB/Swiss-Prot genetic disease variations for Polycythemia Vera:

75
# Symbol AA change Variation ID SNP ID
1 JAK2 p.Val617Phe VAR_032697 rs77375493

ClinVar genetic disease variations for Polycythemia Vera:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 JAK2 NM_004972.3(JAK2): c.1849G> T (p.Val617Phe) single nucleotide variant Pathogenic rs77375493 GRCh37 Chromosome 9, 5073770: 5073770
2 JAK2 NM_004972.3(JAK2): c.1849G> T (p.Val617Phe) single nucleotide variant Pathogenic rs77375493 GRCh38 Chromosome 9, 5073770: 5073770
3 JAK1 NM_002227.3(JAK1): c.1972G> T (p.Val658Phe) single nucleotide variant Likely pathogenic rs1057519753 GRCh37 Chromosome 1, 65312347: 65312347
4 JAK1 NM_002227.3(JAK1): c.1972G> T (p.Val658Phe) single nucleotide variant Likely pathogenic rs1057519753 GRCh38 Chromosome 1, 64846664: 64846664

Expression for Polycythemia Vera

Search GEO for disease gene expression data for Polycythemia Vera.

Pathways for Polycythemia Vera

Pathways related to Polycythemia Vera according to GeneCards Suite gene sharing:

(show top 50) (show all 90)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.12 CD177 IL3 JAK1 JAK2 JAK3 KIT
2
Show member pathways
13.93 EPOR IL3 JAK1 JAK2 JAK3 KIT
3
Show member pathways
13.8 EPOR IL3 JAK1 JAK2 JAK3 KIT
4
Show member pathways
13.74 EPO EPOR IL3 JAK2 JAK3 KIT
5
Show member pathways
13.57 IL3 JAK1 JAK2 JAK3 KIT KITLG
6
Show member pathways
13.48 EPOR IL3 JAK1 JAK2 JAK3 KIT
7
Show member pathways
13.43 IL3 JAK1 JAK2 JAK3 KIT KITLG
8
Show member pathways
13.39 EPOR IL3 KIT KITLG PDGFRA PDGFRB
9
Show member pathways
13.38 CD177 IL3 JAK1 JAK2 JAK3 MPL
10
Show member pathways
13.36 IL3 JAK2 KIT KITLG PDGFRA PDGFRB
11
Show member pathways
13.34 EPOR IL3 KIT KITLG PDGFRA PDGFRB
12
Show member pathways
13.27 EPO EPOR IL3 JAK1 JAK2 JAK3
13
Show member pathways
13.13 IL3 KIT KITLG PDGFRA PDGFRB THPO
14
Show member pathways
13.07 IL3 JAK1 JAK2 KIT KITLG PDGFRA
15
Show member pathways
13.01 EPO EPOR JAK2 KIT KITLG PDGFRA
16
Show member pathways
13 JAK1 JAK2 JAK3 PDGFRA PDGFRB STAT3
17
Show member pathways
13 JAK1 JAK2 JAK3 MPL SOCS3 STAT3
18
Show member pathways
13 EPO EPOR IL3 JAK1 JAK2 JAK3
19
Show member pathways
12.96 EPOR JAK1 JAK2 JAK3 PDGFRA PDGFRB
20
Show member pathways
12.94 IL3 JAK1 KIT PDGFRA PDGFRB STAT3
21
Show member pathways
12.87 JAK1 JAK2 JAK3 SOCS3 STAT3 TYK2
22
Show member pathways
12.87 JAK1 JAK2 JAK3 MPL SOCS3 STAT3
23
Show member pathways
12.85 JAK1 JAK2 JAK3 PDGFRA PDGFRB STAT3
24 12.78 EPO EPOR IL3 JAK1 JAK2 JAK3
25
Show member pathways
12.68 JAK1 JAK2 PDGFRA PDGFRB SOCS3 STAT3
26 12.59 HMGA2 MIR150 PDGFRA PDGFRB STAT3
27
Show member pathways
12.56 IL3 JAK1 JAK2 JAK3 STAT3 TYK2
28
Show member pathways
12.53 JAK1 JAK2 JAK3 STAT3 TYK2
29
Show member pathways
12.52 JAK1 JAK2 SOCS3 STAT3
30 12.47 JAK1 JAK3 PDGFRA PDGFRB
31 12.47 IL3 JAK1 JAK2 JAK3 KIT KITLG
32
Show member pathways
12.45 KIT KITLG PDGFRA PDGFRB
33
Show member pathways
12.45 JAK1 JAK2 JAK3 STAT3
34
Show member pathways
12.36 JAK1 JAK2 STAT3 TYK2
35 12.36 JAK1 JAK3 STAT3 TYK2
36
Show member pathways
12.36 JAK1 JAK2 JAK3 SOCS3 STAT3 TYK2
37
Show member pathways
12.32 JAK1 JAK2 STAT3 TYK2
38
Show member pathways
12.32 JAK1 JAK2 JAK3 STAT3 TYK2
39
Show member pathways
12.32 JAK1 JAK2 JAK3 SOCS3 STAT3 TYK2
40
Show member pathways
12.27 JAK1 JAK2 JAK3 SOCS3 STAT3 TYK2
41
Show member pathways
12.22 IL3 JAK1 JAK2 JAK3
42
Show member pathways
12.21 JAK1 PDGFRA PDGFRB STAT3
43
Show member pathways
12.19 JAK1 JAK2 JAK3 SOCS3 STAT3
44 12.19 JAK2 KIT KITLG PDGFRA PDGFRB SOCS3
45
Show member pathways
12.18 IL3 JAK1 JAK2 KITLG STAT3 THPO
46 12.18 IL3 KITLG PDGFRB STAT3 THPO
47
Show member pathways
12.18 EPO EPOR IL3 JAK1 JAK2 KIT
48 12.17 JAK1 JAK2 JAK3 STAT3
49 12.14 JAK1 SOCS3 STAT3 TYK2
50 12.09 EPO IL3 KIT KITLG MPL THPO

GO Terms for Polycythemia Vera

Cellular components related to Polycythemia Vera according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extrinsic component of cytoplasmic side of plasma membrane GO:0031234 8.92 JAK1 JAK2 JAK3 TYK2

Biological processes related to Polycythemia Vera according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of signal transduction GO:0009968 9.97 KIT PDGFRA PDGFRB SOCS3
2 cell migration GO:0016477 9.97 JAK1 JAK2 JAK3 PDGFRA PDGFRB TYK2
3 phosphatidylinositol phosphorylation GO:0046854 9.95 KIT KITLG PDGFRA PDGFRB
4 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.93 JAK2 KIT PDGFRA PDGFRB
5 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.9 IL3 JAK2 KITLG
6 cell chemotaxis GO:0060326 9.89 KIT PDGFRA PDGFRB
7 positive regulation of kinase activity GO:0033674 9.89 KIT PDGFRA PDGFRB
8 positive regulation of MAP kinase activity GO:0043406 9.88 KIT KITLG PDGFRB
9 peptidyl-tyrosine autophosphorylation GO:0038083 9.88 JAK1 JAK2 JAK3 TYK2
10 interleukin-12-mediated signaling pathway GO:0035722 9.87 JAK1 JAK2 TYK2
11 peptidyl-tyrosine phosphorylation GO:0018108 9.87 IL3 JAK2 JAK3 KIT PDGFRA PDGFRB
12 MAPK cascade GO:0000165 9.86 IL3 JAK1 JAK2 JAK3 KIT KITLG
13 platelet-derived growth factor receptor signaling pathway GO:0048008 9.85 JAK2 PDGFRA PDGFRB
14 erythrocyte differentiation GO:0030218 9.85 EPO JAK2 JAK3 KIT
15 interleukin-7-mediated signaling pathway GO:0038111 9.84 JAK1 JAK3 STAT3
16 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.84 KIT PDGFRA PDGFRB
17 positive regulation of DNA replication GO:0045740 9.84 EPO IL3 KITLG PDGFRA
18 JAK-STAT cascade GO:0007259 9.83 JAK2 SOCS3 STAT3
19 embryonic hemopoiesis GO:0035162 9.81 IL3 KIT KITLG
20 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.8 JAK2 JAK3 STAT3
21 regulation of interferon-gamma-mediated signaling pathway GO:0060334 9.79 JAK1 JAK2 SOCS3
22 interleukin-15-mediated signaling pathway GO:0035723 9.78 JAK1 JAK3 STAT3
23 interleukin-35-mediated signaling pathway GO:0070757 9.77 JAK1 JAK2 STAT3
24 interleukin-23-mediated signaling pathway GO:0038155 9.74 JAK2 STAT3 TYK2
25 positive regulation of phosphoprotein phosphatase activity GO:0032516 9.73 JAK2 PDGFRB
26 response to hyperoxia GO:0055093 9.73 EPO PDGFRB
27 positive regulation of phospholipase C activity GO:0010863 9.73 KIT PDGFRA PDGFRB
28 enzyme linked receptor protein signaling pathway GO:0007167 9.72 JAK2 JAK3
29 interleukin-2-mediated signaling pathway GO:0038110 9.72 JAK1 JAK3
30 growth hormone receptor signaling pathway GO:0060396 9.72 JAK2 STAT3
31 regulation of JAK-STAT cascade GO:0046425 9.71 JAK2 JAK3
32 tyrosine phosphorylation of STAT protein GO:0007260 9.71 JAK2 JAK3
33 negative regulation of platelet-derived growth factor receptor-beta signaling pathway GO:2000587 9.71 PDGFRA PDGFRB
34 interleukin-6-mediated signaling pathway GO:0070102 9.71 JAK1 JAK2 SOCS3 STAT3
35 retina vasculature development in camera-type eye GO:0061298 9.7 PDGFRA PDGFRB
36 ectopic germ cell programmed cell death GO:0035234 9.7 KIT KITLG
37 interleukin-21-mediated signaling pathway GO:0038114 9.7 JAK1 JAK3 STAT3
38 positive regulation of hematopoietic stem cell proliferation GO:1902035 9.69 KITLG THPO
39 interleukin-9-mediated signaling pathway GO:0038113 9.68 JAK1 JAK3
40 positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway GO:0038091 9.68 PDGFRA PDGFRB
41 metanephric glomerular capillary formation GO:0072277 9.68 PDGFRA PDGFRB
42 thrombopoietin-mediated signaling pathway GO:0038163 9.68 MPL THPO
43 interleukin-27-mediated signaling pathway GO:0070106 9.67 JAK1 JAK2 STAT3 TYK2
44 positive regulation of growth factor dependent skeletal muscle satellite cell proliferation GO:1902728 9.65 JAK2 STAT3
45 erythropoietin-mediated signaling pathway GO:0038162 9.63 EPO EPOR KIT
46 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.63 EPO IL3 JAK2 KIT SOCS3 STAT3
47 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.5 JAK1 JAK2 JAK3 KIT PDGFRA PDGFRB
48 cytokine-mediated signaling pathway GO:0019221 9.32 EPOR IL3 JAK1 JAK2 JAK3 KIT
49 cell differentiation GO:0030154 10.24 JAK1 JAK2 JAK3 KIT PDGFRA PDGFRB
50 protein phosphorylation GO:0006468 10.18 JAK1 JAK2 JAK3 KIT PDGFRA PDGFRB

Molecular functions related to Polycythemia Vera according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.98 JAK1 JAK2 JAK3 KIT PDGFRA PDGFRB
2 signaling receptor binding GO:0005102 9.92 JAK1 JAK2 JAK3 PDGFRB TYK2
3 nucleotide binding GO:0000166 9.88 JAK1 JAK2 JAK3 KIT PDGFRA PDGFRB
4 protein kinase activity GO:0004672 9.87 JAK1 JAK2 JAK3 KIT PDGFRA PDGFRB
5 cytokine activity GO:0005125 9.84 EPO IL3 KITLG THPO
6 MAP kinase kinase kinase activity GO:0004709 9.76 KIT PDGFRA PDGFRB
7 protein phosphatase binding GO:0019903 9.73 JAK1 JAK3 STAT3
8 mitogen-activated protein kinase kinase binding GO:0031434 9.72 KIT PDGFRA PDGFRB
9 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.67 KIT PDGFRA PDGFRB
10 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.67 KIT KITLG PDGFRA PDGFRB
11 growth factor binding GO:0019838 9.63 KIT PDGFRA PDGFRB
12 platelet-derived growth factor receptor binding GO:0005161 9.59 PDGFRA PDGFRB
13 platelet-derived growth factor binding GO:0048407 9.58 PDGFRA PDGFRB
14 type 1 angiotensin receptor binding GO:0031702 9.57 JAK2 TYK2
15 non-membrane spanning protein tyrosine kinase activity GO:0004715 9.56 JAK1 JAK2 JAK3 TYK2
16 protein tyrosine kinase activity GO:0004713 9.56 IL3 JAK1 JAK2 JAK3 KIT PDGFRA
17 CCR5 chemokine receptor binding GO:0031730 9.51 JAK1 STAT3
18 vascular endothelial growth factor binding GO:0038085 9.48 PDGFRA PDGFRB
19 growth hormone receptor binding GO:0005131 9.33 JAK1 JAK2 TYK2
20 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.23 IL3 JAK1 JAK2 JAK3 KIT KITLG

Sources for Polycythemia Vera

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....